Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To investigate efficacy, safety and tolerability of BI 1356 versus placebo

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Linagliptin

Criteria

Inclusion criteria:

• Male or female patients with type 2 diabetes and insufficient glycaemic control.

• Age 18 or over and not older than 80 years

Exclusion criteria:

• Use of more than one oral antidiabetic agent within 10 weeks prior to informed consent, insulin, glitazones or GLP-1 analogues within 3 months.

• Myocardial infarction, stroke or transient ischaemic attack within 6 months prior to informed consent.